Abstract
Staphylococcal infections are reported to cause very important problems in hospitalized and immunocompressed patients worldwide due to their tough and irresponsive treatment by antibiotics. Biofilm-embedded bacteria that gain resistance to immune defense and antibiotics by antibiotic degrading enzymes, efflux pumps, and certain gene products of which expression are changed by the quorum sensing cause chronic and recurrent infections such as indwelling device–associated infections. Biofilm-embedded sessile community has heterogeneous cells that have wide range of different responds to each antimicrobials. Staphylococcus epidermidis (S. epidermidis) and Staphylococcus aureus (S. aureus) that are mostly known pathogenic strains can induce gene expression of biofilm that has an important role in the pathogenesis of staphylococcal infections and causes bacterial attachment and colonization on biotic such as tissues or abiotic surfaces such as prosthetic surfaces that may act as a substrate for microbial adhesion when microorganisms exposed to stress conditions. This expressed and matured biofilm causes bacterial spread to whole body, consequently, spread of infection in to whole body. It is hard to treat biofilm infections, and new agents are being researched to prevent formation and dissemination of biofilm. Defining the virulence and the role of biofilm of S. epidermidis and S. aureus in chronic and recurrent infections such as indwelling device–associated infections, the mechanism and the global regulation of biofilm production by quorum-sensing system, inactivation of biofilm formation, and the resistance patterns of biofilm-embedded microorganism against antimicrobials are important.
Keywords
- staphylococcal biofilm
- mechanism and regulation of biofilm formation
- quorum-sensing system
- antimicrobial resistance of biofilm
- Staphylococcus aureus
- Staphylococcus epidermidis
- pathogenicity
1. Introduction
Staphylococci that construct the human skin flora can contaminate indwelling devices. By this way, they are inserted to human by contaminated indwelling devices. When microorganisms exposed to stress conditions, gene expression of biofilm is induced as a stress response. The biofilm that is a slime-like glycocalyx causes bacteria to survive in the stress conditions. Staphylococci adhere, colonize, and infect biotic surfaces such as tissue or abiotic surfaces such as prosthetic surfaces that may act as a substrate for microbial adhesion and causes bacterial spread to whole body by forming biofilm that is a slime-like glycocalyx [1, 4, 5]. The virulence and the role of biofilm of
2. The biofilm, virulence, and Staphylococcus
2.1. The pathogenesis of Staphylococcus biofilm
The biofilm has an important role in the pathogenesis of staphylococcal infections. The biofilm causes bacteria to survive in the stress conditions such as UV damage, metal toxicity, anaerobic conditions, acid exposure, salinity, pH gradients, desiccation, bacteriophages, and amoebae and to resist antibiotics, antimicrobials, and host immune defense [5–8]. The main pathogen of implant infections is staphylococci that cause 80% of all prosthetic infections [9]. The biofilm of bacteria causes chronic infections such as indwelling device–related infections, chronic wound infections, chronic urinary tract infections (UTI), cystic fibrosis pneumonia, chronic otitis media (OM), chronic rhinosinusitis, periodontitis, and recurrent tonsillitis [10]. The biofilm infections are the main important problems in hospitalized and immunocompressed patients in worldwide due to their tough and irresponsive treatment by antibiotics. In biofilm, bacteria are not distrupted completely by antibiotics even high doses of antibiotics used
2.2. Staphylococcal biofilms as a virulence factor
The biofilm that anchored to abiotic or biotic surfaces is a slime-like glycocalyx in which sessile community of microorganisms embedded. This extracellular polymeric substance that is constituted by matrix of polysaccharide, teichoic acids, extracellular DNA (eDNA), and staphylococcal proteins is produced by biofilm producing microorganisms [4, 17, 18]. Polysaccharide intracellular adhesin (PIA) is a specific polysaccharide in glycocalyx composed of β-1,6–linked N-acetylglucosamine residues (80–85%) and non-N-acetylated D-glucosaminyl residues that are an anionic fraction and contain phosphate and ester-linked succinate (15–20%) [18]. Although PIA is a main mechanism of biofilm formation in
2.3. Mechanisms of biofilm formation
Bacterial biofilm formation is a complex and multifactorial process. The biofilm formation process consists of adherence/adhesion/attachment, aggregation/maturation/accumulation, and detachment/dispersal phase. The last step is the dispersal of mature biofilm-embedded bacteria out of the biofilm [21] (Figure 1).
2.3.1. Attachment (adhesion or adherence) phase
When conditions favor biofilm formation, biofilm formation that begins with the adherence of the bacteria to a surface that act as a substrate for microbial adhesion continues with the aggregation formed by cell–cell adhesion [22] (Figure 1).
Staphylococcal adherence to an abiotic surface of indwelling prosthetic device depends on physico-chemical structure of medical device and surface components of Staphylococci such as wall teichoic acid (WTA) [23], lipoteichoic acid (LTA) [23], accumulation-associated protein (Aap) [24], autolysins AtlA [25] and AtlE [26]. The staphylococcal adherence to a biotic surfaces such as host cells and plasma protein-coated prosthetic surface is mediated by cell wall-anchored (CWA) proteins such as the fibrinogen-binding protein SdrG/Fbe of
Several microbial surface components recognizing adhesive matrix molecules (MSCRAMMs) that are able to bind to human matrix proteins such as fibronectin and fibrinogen and colonize are expressed in
2.3.2. Accumulation (aggregation or maturation) phase
After adherence of staphylococcus to biotic and abiotic surfaces, exopolysaccharide (EPS) such as PIA or PNAG that are produced by
In the initial cell-surface interaction of motile bacteria, adherence of motile cell to surface is facilitated by flagella of motile cell. After adherence motile species that undergo cellular differentiation in biofilm lose their motility by paralyzing their flagella and become nonmotile [34]. Klausen et al. [35] revealed that wild-type strain and isogenic flagellar mutant of
2.3.3. The detachment (or dispersal) phase
In the detachment stage, sessile cells turn into planktonic state that can spread and colonize other surfaces and form biofilm on these infected regions [2] (Figure 1). Detachment of microorganisms from biofilm can be caused by bacteria themselves, such as enzymatic degradation of the biofilm matrix such as dissolution of adhesins by proteases, nucleases, and a group of small amphiphilic α-helical peptides, known as phenol-soluble modulins (PSMs) functioning as surfactants [27], and quorum sensing or by external forces such as fluid shear forces, corrosion, and human intervention [36] (Figure 2). During detachment of motile microorganism rather than staphylococcus, cells express genes that are for motility such as transcription of pilus and ribosomal proteins and are almost seen in planktonic cells [37].
2.4. Types of biofilm formation
2.4.1. PIA-dependent biofilm formation
Positively charged PIA provides intercellular attachment via binding to bacteria of which surface is negatively charged [27]. All
2.4.2. PIA-independent biofilm formation
Biofilms not only can be constructed by
PIA-independent biofilms were constructed by accumulation-associated proteins (Aap) of
Scientists determined that medical MRSA isolates produce protein-dependent biofilm such as FnBP- and Aap-dependent biofilms in animal models that have indwelling device–associated infection. O’Neill et al. [30] and McCourt et al. [39] revealed that biofilms of certain isolates of HA-MRSA from CC8 and CC22 and CA-MRSA from USA300 lineage (CC8) were FnBPs-dependent.
Autolysin Atl that is a wall-anchored protein of
In biofilm production of
2.5. The global regulation of biofilm formation
2.5.1. The regulation of Staphylococcal biofilm by agr -quorum-sensing system
Biofilm production is provided by the equilibrium between the productions of amyloid fibrils and phenol soluble modulins (PSMs) that are extracellular polymeric substances and their catabolism by enzymes such as nucleases and proteases that are expressed by agr-QS regulator system that use two-component system signal transduction system (TCS). The control of planktonic and sessile bacteria and the biofilm expression is regulated by coordinated mechanisms [41] (Figure 2).
The biofilm formation of staphylococci is fully expressed
Staphylococcus use quorum-sensing systems (QS) for intercellular communication and biofilm formation. Accessory gene regulator (Agr) system regulates cell density-dependent gene expression using two-component signal transduction system [42]. Agr and LuxS systems that are required for autoinducer peptide (AIP) production as a pheromone are quorum-sensing systems in staphylococci [43]. Bacteria sense pheromones as stimuli that are released by the density of bacteria belonging to the same group and express biofilm formation [9]. AIP production starts in exponential phase of bacterial growth [44]. There are four proteins that are sensor histidine protein kinase AgrC, DNA-binding response regulator AgrA, AgrD that is a prepheromone, and AgrB that exports and modifies AgrD, present in this system. The signal is transported to bacteria by binding of AIP to AgrC. When AIP binds to AgrC, DNA-binding regulator AgrA is activated by His-dependent phosphorylation of AgrC [42]. By the binding of activated DNA-binding regulator AgrA to P2 and P3 promoters in
The regulation mechanisms of RNAIII for target genes can be at transcriptional and translational level, and its regulation can be direct or indirect. Fourteen stem-loop and two long helices construct structure of RNAIII. Each domain regulates the expression of each target gene. Translation of α-hemolysin (
Staphylococcal virulence factors are expressed with accessory gene regulator (agr) system in response to cell density [9]. During the beginning of the biofilm-related staphylococcal infection, adhesion factors (surface proteins) such as MSCRAMMs are upregulated. After initial attachment and colonization had been happened, during early stationary growth phase of bacteria, toxins and other acute virulence factors such as degradative exoenzymes (such as δ-hemolysin, lipases and proteases that disperse bacteria) are upregulated and non-aggressive colonization surface proteins such as MSCRAMMs are downregulated by
The production of PIA/PNAG, PIA/PNAG-degrading enzymes, and matrix components of staphylococcal biofilm is not regulated by QS [44, 46].
Phenol-soluble modulins (PSMs) are surfactant-like staphylococcal peptides and are controlled by
Agr (AIPs) of each strain belongs to different
To control biofilm-associated staphylococcal infections, production of virulence factors and antibiotic resistance, QS can be disrupted by inhibition of signal production, degrading signals, and suppressing synthase and receptors [9].
2.5.2. The regulation of Staphylococcal biofilm by other than Agr
2.5.2.1. sarA
Two-component regulator gene locus encoded by arlRS is regulated by
2.5.2.2. sigB
The
2.5.2.3. ArIRS
The biofilm formation of
2.5.2.4. lytSR
2.5.3. Inactivation of ica by sequences
2.5.3.1. IS256
Although
2.5.3.2. Tetranucleotide tandem repeat
2.6. Treatment of biofilm
To provide protection against
Kaplan et al. [68] and Whitchurch et al. [69] concluded that DNase I in human serum can degrade eDNA in biofilm matrix, by the way bacterial biofilms are degreased.
Nitric oxide (NO) that is a product of anaerobic respiration can cause dispersal of microorganism from mature biofilm by stimulation of c-di-GMP phosphodiesterases activity [70]. c-di-GMP biosynthesis inhibitors can be an alternative treatment for preventing biofilm formation and mature biofilm dispersal. The combinations of dispersin B (EPS-degrading enzymes) and disinfectants such as triclosan with antibiotics that are used in the treatment of wound and skin infections provides synergistic removal of biofilms [71].
3. The mechanisms of antibiotic resistance in biofilm-embedded microorganism
Biofilm-embedded bacteria are more resistant to antimicrobial agents than planktonic bacteria. It is difficult to eradicate biofilm, and this causes serious clinical problem [72].
Antibiotic resistance (tolerance) that is caused by biofilm and permit bacteria to survive is a physiological state by which mutational changes not caused [73]. Impermeability of peptidoglycan by efflux pumps, antibiotic-degrading enzymes, the charge of polymers [73], and certain gene products that are produced in biofilms [3] are the other antibiotic resistance mechanisms of bacteria rather than the biofilm [3]. Biofilm can gain higher antibiotic tolerance by antibiotic degrading enzymes such as beta-lactamases, efflux pumps, and certain gene products of which expression are changed by the quorum sensing as a stress response [3, 74]. Biofilms resist to beta-lactam antibiotics by beta-lactamases. Beta-lactamases that are produced by bacteria play a key factor in the biofilm caused resistance to beta-lactam antibiotics [3].
3.1. The heterogeneous sessile community and the physiology of biofilm
Biofilm-embedded sessile community has heterogeneous cells that are in the different growth states. Bacterial growth rate is reduced by stress conditions such as nutrient and oxygen limitation at the lower parts of the biofilm, and low metabolic activity. Low metabolically active cells (slow growing cells) are seen at the deeper parts of the biofilm, whereas high metabolically active cells (rapid growing cells) are seen at the surfaces of the biofilm. These heterogeneous cells that consist of low and high metabolically active cells have wide range of different responds to each antimicrobial. Antibiotic penetration through the biofilm is reduced by reduced bacterial growth rate. The biofilm-related resistance mechanisms such as oxygen limitation and low metabolic activity, reduced antibiotic penetration through the biofilm, and gaining genetic adaptations such as increased changes in the genes of the DNA repair systems play a key factor in the biofilm tolerance to antibiotics [3]. But some antibiotics such as colistin are just effective against slow-growing cells seen at the deeper parts of the biofilm not against rapid growing cells that acquired adaptive resistance by upregulation of the LPS-modification (arn) operon [75]. Persister cell population that is present in the biofilms of
3.2. Nutrient limitation
Some researchers demonstrated that nutrient limitation-related antibiotic resistance is not due to the reduced growth rate of microorganism, but rather to the activation of regulated stress responses. Nutrient limitation-related antibiotic resistance is controlled by complex regulatory pathways [77]. During starvation, the activation of the stringent response participates in antibiotic resistance such as fluoroquinolone resistance in
3.3. Biofilm matrix
Usually, the decreased antibiotic penetration through the biofilm is caused by antibiotics that may bind to the structural contents of biofilm matrix [3] rather than reduced diffusion of antibiotics through the biofilm matrix [10] (Figure 3).
3.4. Agr expression
Antibiotic susceptibility of biofilm-embedded bacteria decreases according to the planktonic state. The virulence of
Agr expression of biofilm producer staphylococcus has also been associated with the drug resistance of some antibiotics. It has been also revealed that the effect of rifampin against
References
- 1.
Otto M. Staphylococcal biofilms. In: Romeo T (ed), Bacterial Biofilms. Current Topics in Microbiology and Immunology. Springer Berlin Heidelberg. 2008;322:207–228. DOI: 10.1007/978-3-540-75418-3_1Online ISBN: 978-3-540-75418-3 - 2.
Stoodley P, Sauer K, Davies DG and Costerton JW. Biofilms as complex differentiated communities. Annu Rev Microbiol. 2002;56:187–209. - 3.
Bjarnsholt T, Moser C, Jensen PO and Hoiby N. Biofilm Infections. New York Dordrecht Heidelberg London: Springer Science Business Media, LLC; 2011. 215–225 p. - 4.
Donlan RM and Costerton JW. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev. 2002;15:167–193. - 5.
Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME and Shirtliff ME. Staphylococcus aureus biofilms: properties, regulation, and roles in human disease. Virulence. 2011;2:445–459. - 6.
Römling U and Balsalobre C. Biofilm infections, their resilience to therapy and innovative treatment strategies. J Intern Med. 2012;272(6):541–561. - 7.
Hall-Stoodley L, Costerton JW and Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nat Rev Microbiol. 2004;2:95–108. - 8.
Costerton JW, Stewart PS and Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999;284:1318–1322. - 9.
Arciola CR, Campoccia D, Ravaioli S and Montanaro L. Polysaccharide intercellular adhesin in biofilm: structural and regulatory aspects. Front Cell Infect Microbiol. 2015;5:1–10. - 10.
Hall-Stoodley L and Stoodley P. Evolving concepts in biofilm infections. Cell Microbiol. 2009;11(7):1034–1043. - 11.
Harbarth S, Masuet-Aumatell C, Schrenzel J, Francois P, Akakpo C, Renzi G, et al. Evaluation of rapid screening and pre-emptive contact isolation for detecting and controlling methicillin-resistant Staphylococcus aureus in critical care: an interventional cohort study. Crit Care. 2006;10(1):R25. - 12.
Darouiche RO. Treatment of infections associated with surgical implants. N Engl J Med. 2004;350:1422–1429. - 13.
Costerton JW. Biofilm theory can guide the treatment of device related orthopaedic infections. Clin Orthop Relat Res. 2005;437:7–11. - 14.
Gandelman G, Frishman WH, Wiese C, Green-Gastwirth V, Hong S, Aronow WS, et al. Intravascular device infections: epidemiology, diagnosis, and management. Cardiol Rev. 2007;15:13–23. - 15.
Nablo BJ, Prichard HL, Butler RD, Klitzman B and Schoenfisch MH. Inhibition of implant-associated infections via nitric oxide release. Biomaterials. 2005;26(34):6984–6990. - 16.
Trampuz A and Widmer AF. Infections associated with orthopedic implants. Curr Opin Infect Dis. 2006;19:349–356. - 17.
Flemming HC and Wingender J. The biofilm matrix. Nat Rev Microbiol. 2010;8:623–633. - 18.
Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME and Shirtliff ME. Staphylococcus aureus biofilms: properties, regulation and roles in human disease. Virulence. 2011;2(5)445–459. - 19.
Anderl JN, Franklin MJ and Stewart PS. Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob Agents Chemother. 2000;44:1818–1824. - 20.
Mulcahy H, Charron-Mazenod L and Lewenza S. Extracellular DNA chelates cations and induces antibiotic resistance in Pseudomonas aeruginosa biofilms. Plos Pathog. 2008;4:e1000213. - 21.
Otto M. Staphylococcal infections: mechanisms of biofilm maturation. Annu Rev Med. 2013;64:175–188. - 22.
Kuroda M, Ito R, Tanaka Y, Yao M, Matoba K, Saito S, et al. Staphylococcus aureus surface protein SasG contributes to intercellular autoaggregation ofStaphylococcus aureus . Biochem Biophys Res Commun. 2008;377:1102–1106. - 23.
Gross M, Cramton SE, Gotz E and Peschel A. Key role of teichoic acid net charge in Staphylococcus aureus colonization of artificial surfaces. Infect Immun. 2001;69:3423–3426. - 24.
Conlon BP, Geoghegan JA, Waters EM, McCarthy H, Rowe SE, Davies JR, et al. A role for the A-domain of unprocessed accumulation associated protein (Aap) in the attachment phase of the Staphylococcus epidermidis biofilm phenotype. J Bacteriol. 2014;196:4268–4275. - 25.
Houston P, Rowe SE, Pozzi C, Waters EM and O’Gara JP. Essential role for the major autolysin in the fibronectin-binding protein-mediated Staphylococcus aureus biofilm phenotype. Infect Immun. 2011;79:1153–1165. - 26.
Rupp ME, Fey PD, Heilmann C and Götz F. Characterization of the importance of Staphylococcus epidermidis autolysin and polysaccharide intercellular adhesin in the pathogenesis of intravascular catheter-associated infection in a rat model. J Infect Dis. 2001;183:1038–1042. - 27.
Speziale P, Pietrocola G, Foster TJ and Geoghegan JA. Protein-based biofilm matrices in Staphylococci. Front Cell Infect Microbiol. 2014;4:171. doi:10.3389/fcimb.2014.00171 - 28.
Patti JM, Allen BL, McGavin MJ and Hook M. MSCRAMM-mediated adherence of microorganisms. Annu Rev Microbiol. 1994;48:585–617. - 29.
Latasa C, Solano C, Penadés JR and Lasa I. Biofilm-associated proteins. C R Biol. 2006;329:849–857. - 30.
O’Neill E, Pozzi C, Houston P, Humphreys H, Robinson DA, et al. A novel Staphylococcus aureus biofilm phenotype mediated by the fibronectin-binding proteins, FnBPA and FnBPB. J Bacteriol. 2008;190:3835–3850. - 31.
Plata K, Rosato AE and Wegrzyn G. Staphylococcus aureus as an infectious agent: overview of biochemistry and molecular genetics of its pathogenicity. Acta Biochim Pol. 2009;56(4):597–612. - 32.
Heilmann C, Schweitzer O, Gerke C, Vanittanakom N, Mack D. and Götz F. Molecular basis of intercellular adhesion in the biofilm-forming Staphylococcus epidermidis . Mol Microbiol. 1996;20:1083–1091. - 33.
Foster TJ, Geoghegan JA, Ganesh VK and Hook M. Adhesion, invasion and evasion: the many functions of the surface proteins of Staphylococcus aureus . Nat Rev Microbiol. 2014;12:49–62. - 34.
Spormann AM. Physiology of microbes in biofilms. In: Romeo T (ed), Bacterial Biofilms. Germany: Springer–Verlag Berlin Heidelberg; 2008;322:17–36. - 35.
Klausen M, Aaes-Jorgensen A, Molin S and Tolker-Nielsen T. Biofilm formation by Pseudomonas aeruginosa wild type, flagella, and type IV pili mutants. Mol Microbiol. 2003;48:1511–1524. - 36.
Kaplan JB. Biofilm dispersal: mechanisms, clinical implications, and potential therapeutic uses. J Dent Res. 2010;89:205–218. - 37.
Sauer K, Camper AK, Ehrlich GD, Costerton JW and Davies DG. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J Bacteriol. 2002;184(4):1140–1154. - 38.
Fitzpatrick F, Humphreys H and O’Gara JP. Evidence for icaADBC-independent biofilm development mechanism in methicillin-resistant Staphylococcus aureus clinical isolates. J Clin Microbiol. 2005;43:1973–1976. - 39.
McCourt J, O’Halloran DP, McCarthy H, O’Gara JP and Geoghegan JA. Fibronectin-binding proteins are required for biofilm formation by community-associated methicillin-resistant Staphylococcus aureus strain LAC. FEMS Microbiol Lett. 2014;353:157–164. - 40.
Huseby MJ, Kruse AC, Digre J, Kohler PL, Vocke JA, Mann EE, et al. Beta toxin catalyzes formation of nucleoprotein matrix in staphylococcal biofilms. Proc Natl Acad Sci USA. 2010;107:14407–14412. - 41.
Schwartz K, Syed AK, Stephenson RE, Rickard AH and Boles BR. Functional amyloids composed of phenol soluble modulins stabilize Staphylococcus aureus biofilms. Plos Pathog. 2012;8:e1002744. - 42.
Le KY, Dastgheyb S, Vo TV and Otto M. Molecular determinants of staphylococcal biofilm dispersal and structuring. Front Cell Infect Microbiol. 2014;4:167. - 43.
O’Gara JP. ica and beyond: biol mechanisms and regulation in Staphylococcus epidermidis andStaphylococcus aureus . FEMS Microbiol Lett. 2007;270:179–188. - 44.
Singh R and Ray P. Quorum sensing-mediated regulation of staphylococcal virulence and antibiotic resistance. Future Microbiol. 2014;9(5):669–681. - 45.
Felden B, Vandenesch F, Bouloc P and Romby P. The Staphylococcus aureu s RNome and its commitment to virulence. Plos Pathog. 2011;7(3):e1002006. - 46.
Joo HS and Otto M. Molecular basis of in-vivo biofilm formation by bacterial pathogens. Chem Biol. 2012;19(12):1503–1513. - 47.
Shopsin B, Eaton C, Wasserman GA, Mathema B, Adhikari RP, Agolory S, Altman DR, Holzman RS, Kreiswirth BN and Novick RP. Mutations in agr do not persist in natural populations of methicillin resistant Staphylococcus aureus . J Infect Dis. 2010;202:1593–1599. - 48.
Wang R, Khan BA, Cheung GY, Bach TH, Jameson-Lee M, Kong KE, et al. Staphylococcus epidermidis surfactant peptides promote biofilm maturation and dissemination of biofilm-associated infection in mice. J Clin Investig. 2011;121:238–248. - 49.
Periasamy S, Joo HS, Duong AC, Bach TH, Tan VY, Chatterjee SS, Cheung GY and Otto M. How Staphylococcus aureus biofilms develop their characteristic structure. Proc Natl Acad Sci USA. 2012;109:1281–1286. - 50.
Beenken KE, Spencer H, Griffin LM and Smeltzer MS. Impact of extracellular nuclease production on the biofilm phenotype of Staphylococcus aureus underin vitro andin vivo conditions. Infect Immun. 2012;80:1634–1638. - 51.
Hochbaum AI, Kolodkin-Gal I, Foulston L, Kolter R, Aizenberg J and Losick R. Inhibitory effects of D-amino acids on Staphylococcus aureus biofilm development. J Bacteriol. 2011;193:5616–5622. - 52.
Cafiso V, Bertuccio T, Santagati M, et al. agr-Genoty ping and transcriptional analysis of biofilm-producing Staphylococcus aureus . FEMS Immunol Med Microbiol. 2007;51(1):220–227. - 53.
Bhatty M, Ray P, Singh R, Jain S and Sharma M. Presence of virulence determinants amongst Staphylococcus aureus isolates from nasal colonization, superficial & invasive infections. Indian J Med Res. 2013;138(1):143–146. - 54.
De Sanctis JT, Swami A, Sawarynski K, et al. Is there a clinical association of vancomycin MIC creep, agr group II locus, and treatment failure in MRSA bacteremia? Diagn Mol Pathol. 2011;20(3):184–188. - 55.
Mack D, Davies AP, Harris LG, Rohde H, Horstkotte MA and Knobloch JK. Microbial interactions in Staphylococcus epidermidis biofilms. Anal Bioanal Chem. 2007;387(2):399–408. - 56.
Yarwood JW and Schlievert PM. Quorum sensing in Staphylococcus infections. J Clin Investig. 2003;112(11):1620–1625. - 57.
Zhu T, Lou Q, Wu Y, Hu J, Yu E and Qu D. The impact of the Staphylococcus epidermidis LytSR two-component regulatory system on murein hydrolase activity, pyruvate utilization and global transcriptional profile. BMC Microbiol. 2010;10:287. - 58.
Fournier B and Hooper DC. A new two-component regulatory system involved in adhesion, autolysis, and extracellular proteolytic activity of Staphylococcus aureus . J Bacteriol. 2000;182:3955–3964. - 59.
Wu Y, Wang J, Xu T, Liu J, Yu W, Lou Q, et al. The two-component signal transduction system ArlRS regulates Staphylococcus epidermidis biofilm formation in an ica-dependent manner. Plos One. 2012;7:e40041. - 60.
Rice KC and Bayles KW. Molecular control of bacterial death and lysis. Microbiol Mol Biol Rev. 2008;72:85–109. - 61.
Brunskill EW and Bayles KW. Identification of LytSR-regulated genes from Staphylococcus aureus . J Bacteriol. 1996;178:5810–5812. - 62.
Ziebuhr W, Krimmer V, Rachid S, Lössner I, Götz F and Hacker J. A novel mechanism of phase variation of virulence in Staphylococcus epidermidis : evidence for control of the polysaccharide intercellular adhesin synthesis by alternating insertion and excision of the insertion sequence element IS256. Mol Microbiol. 1999;32:345–356. - 63.
Kiem S, Oh WS, Peck KR, Lee NY, Lee JY, Song JH, et al. Phase variation of biofilm formation in Staphylococcus aureus by IS256 insertion and its impact on the capacity adhering to polyurethane surface. J Korean Med Sci. 2004;19:779–782. - 64.
Brooks JL and Jefferson KK. Phase variation of poly-N-acetylglucosamine expression in Staphylococcus aureus . Plos Pathog. 2014;10:e1004292. - 65.
Cerca N, Jefferson KK, Maira-Litrán T, Pier DB, Kelly-Quintos C, Goldmann DA, et al. Molecular basis for preferential protective. Infect Immun. 2007;75:3406–3413. - 66.
Maira-Litrán T, Bentancor LV, Bozkurt-Guzel C, O’Malley JM, Cywes-Bentley C and Pier GB. Synthesis and evaluation of a conjugate vaccine composed of Staphylococcus aureus poly-N-acetyl-glucosamine and clumping factor A. Plos One. 2012;7:e43813. - 67.
Brady RA, O’May GA, Leid JG, Prior ML, Costerton JW and Shirtliff ME. Resolution of Staphylococcus aureus biofilm infection using vaccination and antibiotic treatment. Infect Immun. 2011;79:1797–1803. - 68.
Kaplan JB, LoVetri K, Cardona ST, Madhyastha S, Sadovskaya I, Jabbouri S and Izano EA. Recombinant human DNase I decreases biofilm and increases antimicrobial susceptibility in staphylococci. J Antibiot (Tokyo). 2012;65:73–77. - 69.
Whitchurch CB, Tolker-Nielsen T, Ragas PC and Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science. 2002;295:1487. - 70.
Barraud N, Schleheck D, Klebensberger J, Webb JS, Hassett DJ, Rice SA and Kjelleberg S. Nitric oxide signaling in Pseudomonas aeruginosa biofilms mediates phosphodiesterase activity, decreased cyclic di-GMP levels, and enhanced dispersal. J Bacteriol. 2009;191:7333–7342. - 71.
Darouiche RO, Mansouri MD, Gawande PV and Madhyastha S. Antimicrobial and antibiofilm efficacy of triclosan and dispersinB combination. J Antimicrob Chemother. 2009;64:88–93. - 72.
Hoyle BD and Costerton JW. Bacterial resistance to antibiotics: the role of biofilms. Prog Drug Res. 1991;37:91–105. - 73.
Walters MC, Roe F, Bugnicourt A, Franklin MJ and Stewart PS. Contributions of antibiotic penetration oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to Ciprofloxacin and Tobramycin. Antimicrob Agents Chemother. 2003;47:317–323. - 74.
Antunes LC, Ferreira RB, Buckner MM and Finlay BB. Quorum sensing in bacterial virulence. Microbiol. 2010;156:2271–2282. - 75.
Pamp SJ, Gjermansen M, Johansen HK and Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol. 2008;68:223–240. - 76.
Qu Y, Daley AJ, Istivan TS, Rouch DA and Deighton MA. Densely adherent growth mode, rather than extracellular polymer substance matrix build-up ability, contributes to high resistance of Staphylococcus epidermidis biofilms to antibiotics. J Antimicrob Chemother. 2010;65:1405–1411. - 77.
Nguyen D, Joshi-Datar A, Lepine F, Bauerle E, Olakanmi O, Beer K, McKay G, Siehnel R, Schafhauser J, Wang Y, Britigan BE and Singh PK. Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. Science. 2011;334(6058):982–986. - 78.
Schaible B, Taylor CT and Schaffer K. Hypoxia increases antibiotic resistance in Pseudomonas aeruginosa through altering the composition of multidrug efflux pumps. Antimicrob Agents Chemother. 2012;56:2114–2118. - 79.
Yarwood JM, Bartels DJ, Volper EM and Greenberg EP. Quorum sensing in Staphylococcus aureus biofilms. J Bacteriol. 2004;186(6):1838–1850. - 80.
Paulander W, Nissen Varming A, Baek KT, Haaber J, Frees D and Ingmer H. Antibiotic mediated selection of quorum-sensing negative Staphylococcus aureus . MBio. 2013;3(6):e00459–00412. - 81.
Cameron DR, Howden BP and Peleg AY. The interface between antibiotic resistance and virulence in Staphylococcus aureus and its impact upon clinical outcomes. Clin Infect Dis. 2011;53(6):576–582.